DATATRAK Awarded Three Phase III Studies

CLEVELAND, Oct. 11 /PRNewswire-FirstCall/ — DATATRAK
International, Inc. (OTCQX: DATA), a technology and services
company focused on global eClinical solutions for the clinical
trials industry, today announced the signing of an Enterprise
Agreement for three new Phase III oncology studies with an existing
client. These multi-center studies will be deployed utilizing the
unified DATATRAK eClinical™ platform.

“DATATRAK is pleased to have three new oncology studies running
on our unified eClinical platform. With over 1 million new patients
diagnosed with cancer each year and less than 5% of them being
enrolled in clinical trials, we are excited to participate in
trials with innovative compounds that hold the promise of a cure,”
said Laurence P. Birch, DATATRAK’s Chairman and CEO. “Our knowledge
of the complex and unique requirements related to oncology trials
has been built into DATATRAK eClinical™; these
oncology-specific solutions within our unified platform provide our
clients with the necessary tools to deliver clinical trials with
safety, simplicity and speed.”

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services
company delivering eClinical solutions and related services for the
clinical trials industry. DATATRAK built its multi-component,
comprehensive solution on a single, unified platform and expanded
this concept to include services delivery in DATATRAK ONE™,
the seamless delivery of product and services. The Company delivers
a complete portfolio of software products designed to accelerate
the reporting of clinical research data from sites to sponsors and
ultimately regulatory authorities, faster and more efficiently than
loosely integrated technologies. The DATATRAK eClinical™
software solution, deployed worldwide through an ASP or Enterprise
Transfer offering, has successfully supported hundreds of
international clinical trials involving thousands of clinical
resea

‘/>”/>

SOURCE